Patent: 10,941,210
✉ Email this page to a colleague
Summary for Patent: 10,941,210
| Title: | Anti-PCSK9 antibodies |
| Abstract: | An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements. |
| Inventor(s): | Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald |
| Assignee: | Regeneron Pharmaceuticals Inc |
| Application Number: | US15/996,773 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: |
More… ↓ |
Details for Patent 10,941,210
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | PRALUENT | alirocumab | Injection | 125559 | July 24, 2015 | 10,941,210 | 2038-06-04 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,941,210
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 201103762 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2010077854 | ⤷ Start Trial |
| Uruguay | 32329 | ⤷ Start Trial |
| United States of America | 10023654 | ⤷ Start Trial |
| United States of America | 12269897 | ⤷ Start Trial |
| United States of America | 2010166768 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
